Free shipping on all orders over $ 500
About 30 results found for searched term "BTK" (0.022 seconds)
| Cat.No. | Name | Information |
|---|---|---|
| M1825 | PCI-32765 | PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM. |
| M2113 | Spebrutinib (AVL-292) | Spebrutinib (AVL-292) is an oral, potent and selective small molecule covalent inhibitor of Btk (IC50 < 0.5 nM). |
| M2536 | CNX-774 | CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM. |
| M2718 | GDC-0834 | GDC-0834 is a novel potent and selective BTK inhibitor with IC50 of 5.9 nM. |
| M3620 | CGI1746 | CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM. |
| M3704 | RN486 | RN486 is a Bruton's tyrosine kinase (Btk) inhibitor with an IC50 Value of 4.0 nM. |
| M5133 | Olmutinib | Olmutinib is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
| M5162 | ONO-4059 analogue | ONO-4059 analogue is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with IC50 of 23.9 nM. |
| M5257 | ONO-4059 hydrochloride | ONO-4059 (GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM. |
| M5306 | Acalabrutinib | Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.BMX, and TEC, respectively) and no activity against EGFR. |
| M5333 | Tirabrutinib (ONO-4059) | Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
| M10604 | Pirtobrutinib (LOXO-305) | Pirtobrutinib (LOXO-305; LY 3527727; RXC-005) is a highly selective and non-covalent next generation BTK inhibitor, which inhibits diverse BTK C481 substitution mutations. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases. |
| M6907 | LFM-A13 | LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM. |
| M7120 | PF 06465469 | PF 06465469 is a potent ITK inhibitor; also inhibits BTK. |
| M7536 | BMS-935177 | BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. |
| M8887 | Btk inhibitor 2 | Btk inhibitor 2 (BGB-3111) is a Brutons tyrosine kinase (BTK) inhibitor. |
| M8941 | GDC-0853 (Fenebrutinib) | GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. |
| M9166 | BMS-986142 | BMS-986142 is a potent, selective, reversible BTK inhibitor, shows BTK IC50 = 0.5nM; human WB IC50 = 90 nM. |
| M9628 | Branebrutinib | Branebrutinib (BMS-986195) is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), with IC50 of 0.1 nM. |
| M9889 | PCI-29732 | PCI-29732 is a potent, reversible BTK inhibitor. |
| M9958 | ARQ 531 | ARQ 531 is a potent reversible inhibitor of BTK (IC50 = 0.85 nM), exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma. |
| M10025 | Zanubrutinib | Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
| M10095 | Orelabrutinib | Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). |
| M10274 | Tolebrutinib | Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier capable bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 0.4 and 0.7 nM in Ramos B cells and HMC microglia, respectively. Tolebrutinib has an effect on central nervous system immunity. Tolebrutinib can be used in multiple sclerosis (MS) studies. |
| M10386 | MT-802 | MT-802 is a potent BTK degrader based on PROTAC technology, it induces Bruton's tyrosine kinase (BTK) knockdown. |
| M10500 | Remibrutinib (LOU064) | Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU). |
| M10605 | Rilzabrutinib | Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of 1.3 nM. |
| M10850 | Luxeptinib | Luxeptinib (CG-806) is an orally active, reversible, best-in-class, non-covalent, potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle blocking, apoptosis, or autophagy in acute myeloid leukemia. |
| M10896 | Vecabrutinib | Vecabrutinib (SNS-062) is a potent, non-covalent BTK and ITK inhibitor,Kd The values are 0.3 nM and 2.2 nM, respectively. Vecabrutinib for ITK IC50 The value is 24 nM. |
| M11417 | (S)-Sunvozertinib | (S)-Sunvozertinib ((S)-DZD9008) is the S-enantiomer of Sunvozertinib, EGFR exon 20 NPH and ASV insertion, EGFR L858R/T790M mutation and Her2 exon 20 YVMA insertion (IC50 was 51.2 nM, 51.9 nM, 1 nM and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
